Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer (Q33377144)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer (English)

1 reference

Europe PubMed Central

26 July 2017

phase II clinical trial

0 references

0 references

head and neck cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck carcinoma

1 reference

based on heuristic

inferred from title

Vassiliki Papadimitrakopoulou

3

object named as

Vassiliki A Papadimitrakopoulou

1 reference

Europe PubMed Central

26 July 2017

George R Blumenschein

1

object named as

George R Blumenschein

1 reference

Europe PubMed Central

26 July 2017

author name string

Merrill S Kies

2

1 reference

Europe PubMed Central

26 July 2017

Charles Lu

4

1 reference

Europe PubMed Central

26 July 2017

Ashok J Kumar

5

1 reference

Europe PubMed Central

26 July 2017

Justin L Ricker

6

1 reference

Europe PubMed Central

26 July 2017

Judy H Chiao

7

1 reference

Europe PubMed Central

26 July 2017

Cong Chen

8

1 reference

Europe PubMed Central

26 July 2017

Stanley R Frankel

9

1 reference

Europe PubMed Central

26 July 2017

publication date

25 October 2007

1 reference

Europe PubMed Central

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

26 July 2017

26

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

81-87

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-007-9075-2

0 references

Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-007-9075-2

21 January 2018

A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2005

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth inhibitory effects and radiosensitization induced by fatty aromatic acids on human cervical cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemical agents that promote chromatin compaction radiosensitize tumour cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospects: histone deacetylase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histone deacetylases and cancer: causes and therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel HDAC inhibitors with radiosensitizing properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin, raltitrexed, levofolinic acid and 5-fluorouracil in locally advanced or metastatic squamous cell carcinoma of the head and neck: a phase II randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/17960324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-007-9075-2

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

release_ahl6a6npt5ceflzrtxba7wjw3m

1 reference

https://api.fatcat.wiki/v0/release/ahl6a6npt5ceflzrtxba7wjw3m

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33377144&oldid=1962424760"